DIACARTA INC 4385 Hopyard Road, Suite 100, Pleasanton, CA 94588

CLIA#: 05D2110800; **CAP#:** 9374716
Medical Director: Chuanyi Mark Lu, MD
Email: information@diacarta.com
Phone: (800)246-8878

LABORATORY REPORT

PATIENT			
Name:	TEST, PATIENT		
Address:	101 Main Street, #1 Pleasanton, CA 94588		
Phone:	(631) 000-0000	ID:	ID1989M
Date of Birth: 01/01/1974		Gender:	Male
Race:	White		

SPECIMEN
Type: Urine
Collection Date: 08/30/22
Received Date: 08/30/22
Reported Date: 09/03/22
Accession #: 2311300005

PHYSICIAN	
ID: 1990	NPI: XXXX
Name: 2ND TEST CLIENT	
Address: 11 Grace Av, 208 Pleasanton, CA 94588	
Phone: (000) 000-0000	
Referring: 1988 DOCTOR Dr.	

UriFind™ Test Report

Test Results: Negative Test Result

Normal Value (Reference Range): *Negative*

Interpretation:

A NEGATIVE UriFind result means that none of the methylation markers was detected in the submitted specimen, and that patient is at Low Risk of having urothelial carcinoma. The result should be reviewed by a physician, and clinical evaluation and follow up are recommended.

A POSITIVE UriFind result means that the methylation marker(s) were detected in the submitted specimen, and that the patient is at High Risk of having urothelial carcinoma, or bladder cancer. The result should be reviewed by a physician and followed up by other diagnostic evaluations.

TEST DESCRIPTION

The UriFind test is a non-invasive fluorescence quantitative PCR assay, based on the detection of DNA methylation markers (ONECUT2 and VIM) present in urine-exfoliated cell samples. The test is suited for patients diagnosed with clinical hematuria or patients recommended for cystoscopy by a physician. It can provide physicians/patients with an auxiliary diagnosis option for urothelial carcinoma but cannot be solely used as a basis for tumor diagnosis. Clinicians should judge the diagnosis comprehensively based on the patient's condition and other laboratory tests.